A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Inclusion Criteria:

• Have a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) scale
• Have a life expectancy of greater than or equal to 12 weeks
• Males and females with reproductive potential agree to use medically approved contraceptive precautions during the trial and for three months following the last dose of study drug
• Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic disease for which no proven effective therapy exists.
• Have the presence of measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors.
• Have adequate hematologic, hepatic, and renal function.
• Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy, or other investigational therapy for at least 30 days (6 weeks for mitomycin-C or nitrosoureas) prior to study enrollment and recovered from the acute effects of therapy.

Exclusion Criteria:

• Have received treatment within 30 days of the initial dose of study drug with a drug that has not received regulatory approval for any indication.
• Have serious preexisting medical conditions (left to the discretion of the investigator).
• Have one of the following conduction abnormalities: QTc prolongation >450 msec on screening electrocardiogram (ECG), previous history of QTc prolongation with another medication that required discontinuation, congenital long-QT-syndrome, or left bundle branch block (LBBB).
• Are taking any concomitant medication that may cause QTc prolongation, or induce Torsades de Pointes.
• Have systolic blood pressure greater than/equal to 140 mm Hg, and diastolic blood pressure greater than/equal to 90 mm Hg that is not controlled by medical therapy.
• Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class II or higher. Patients with a history of arrhythmia which is symptomatic or requires treatment.
• Have chronic atrial fibrillation and/or bradycardia.
• Have uncorrected electrolyte disorders including potassium <3.4 mEq/L (<3.4 mmol/l), calcium <8.4 mg/dL (2.1 mmol/L), or magnesium <1.2 mg/dL (<0.62 mmol/L).
• Have symptomatic central nervous system malignancy or metastasis (screening not required).
• Have a hematologic malignancy.
• Females who are pregnant or lactating.